Recurrent Hodgkin lymphoma: toward a new definition of candidates for autologous stem cell transplant in the era of positron emission tomography scan and novel agents

References

• Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomized trial. Lancet 1993;341:1051–1054.
   PubMed Web of Science ®Google Scholar
• Sureda A, Pereira MI, Dreger P. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. The role of hematopoietic stem cell transplantation in the treatment of relapsed/refractory Hodgkin's lymphoma. Curr Opin Oncol 2012;24:727–732.
   PubMed Web of Science ®Google Scholar
• Rancea M, Monsef I, von Tresckow B, et al. High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphoma. Cochrane Database Syst Rev 2013;(6):CD009411.
   Web of Science ®Google Scholar
• Sirohi B, Cunningham D, Powles R, et al. Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma. Ann Oncol 2008;19:1312–1319.
   PubMed Web of Science ®Google Scholar
• Martínez C, Canals C, Sarina B, et al. Identification of prognostic factors predicting outcome in Hodgkin's lymphoma patients relapsing after autologous stem cell transplantation. Ann Oncol 2013;24: 2430–2434.
   PubMed Web of Science ®Google Scholar
• Moskowitz AJ, Perales MA, Kewalramani T, et al. Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma. Br J Haematol 2009;146:158–163.
   PubMed Web of Science ®Google Scholar
• Smith SD, Moskowitz CH, Dean R, et al. Autologous stem cell transplant for early relapsed/refractory Hodgkin lymphoma: results from two transplant centres. Br J Haematol 2011;153:358–363.
   PubMed Web of Science ®Google Scholar
• von Tresckow B, Müller H, Eichenauer DA, et al. Outcome and risk factors of patients with Hodgkin Lymphoma who relapse or progress after autologous stem cell transplant. Leuk Lymphoma 2014;55: 1922–1924.
   PubMed Web of Science ®Google Scholar
• Sureda A, Arranz R, Iriondo A, et al. Autologous stem-cell transplantation for Hodgkin’s disease: results and prognostic factors in 494 patients from the Grupo Español de Linfomas/TransplanteAutólogo de Médula Osea Spanish Cooperative Group. J Clin Oncol 2001;19: 1395–1404.
   PubMed Web of Science ®Google Scholar
• Horning SJ, Chao NJ, Negrin RS, et al. High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices. Blood 1997;89:801–813.
   PubMed Web of Science ®Google Scholar
• Crump M, Smith AM, Brandwein J, et al. High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: importance of disease status at transplant. J Clin Oncol 1993;11:704–711.
   PubMed Web of Science ®Google Scholar
• Lavoie JC, Connors JM, Phillips GL, et al. High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver. Blood 2005;106:1473–1478.
   PubMed Web of Science ®Google Scholar
• Burns LJ, Daniels KA, McGlave PB, et al. Autologous stem cell transplantation for refractory and relapsed Hodgkin’s disease: factors predictive of prolonged survival. Bone Marrow Transplant 1995;16:13–18.
   PubMed Web of Science ®Google Scholar
• Hertzberg M. Relapsed/refractory Hodgkin lymphoma: what is the best salvage therapy and do we need RIC-alloSCT ? Hematol Oncol Clin North Am 2014;28:123–147.
   PubMed Web of Science ®Google Scholar
• Gallamini A, Kostakoglu L. Interim FDG-PET in Hodgkin lymphoma: a compass for a safe navigation in clinical trials? Blood 2012;120:4913–4920.
   PubMed Web of Science ®Google Scholar
• Aldinucci D, Gloghini A, Pinto A, et al. The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape. J Pathol 2010;221:248–263.
   PubMed Web of Science ®Google Scholar
• Steidl C, Connors JM, Gascoyne RD. Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment. J Clin Oncol 2011;29:1812–1826.
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Yahalom J, Zelenetz AD, et al. High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging. Br J Haematol 2010;148:890–897.
   PubMed Web of Science ®Google Scholar
• Moskowitz AJ, Yahalom J, Kewalramani T, et al. Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Blood 2010;116:4934–4937.
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Matasar MJ, Zelenetz AD, et al. Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood 2012;119:1665–1670.
   PubMed Web of Science ®Google Scholar
• Devillier R, Coso D, Castagna L, et al. Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin's lymphoma responding to prior salvage therapy. Haematologica 2012;97:1073–1079.
   PubMed Web of Science ®Google Scholar
• Hutchings M. Pre-transplant positron emission tomography/computed tomography (PET/CT) in relapsed Hodgkin lymphoma: time to shift gears for PET-positive patients ? Leuk Lymphoma 2011;52:1615–1616.
   PubMed Web of Science ®Google Scholar
• Von Tresckow B, Engert A. The emerging role of PET in Hodgkin lymphoma patients receiving autologous stem cell transplant. Expert Rev Hematol 2012;5:483–486.
   PubMed Web of Science ®Google Scholar
• Akhtar S, Al-Sugair AS, Abouzied M, et al. Pre-transplant FDG-PET-based survival model in relapsed and refractory Hodgkin's lymphoma: outcome after high-dose chemotherapy and auto-SCT. Bone Marrow Transplant 2013;48:1530–1536.
   PubMed Web of Science ®Google Scholar
• Peters WP, Dansey R, Baynes RD. Section 16: Bone Marrow Transplantation, Chapter 68: Autologous Bone Marrow and Stem Cell Transplantation.
   Google Scholar
• Collins GP, Parker AN, Pocock C, et al. Guideline on the management of primary resistant and relapsed classical Hodgkin lymphoma. Br J Haematol 2014;164:39–52.
   PubMed Web of Science ®Google Scholar
• Van Den Neste E, Casasnovas O, André M, et al. Classical Hodgkin's lymphoma: the Lymphoma Study Association guidelines for relapsed and refractory adult patients eligible for transplant. Haematologica 2013;98:1185–1195.
   PubMed Web of Science ®Google Scholar
• Moskowitz A, Maragulia JC, Kumar A, et al. Semi-quantitative evaluation of pre-transplant FDG-PET in relapsed and refractory Hodgkin lymphoma. Blood 2012;120(Suppl. 1): Abstract 2015.
   Google Scholar
• Barrington SF, Mikhaeel G, Kostakoglu L, et al. Role of imaging in staging and response assessment of lymphoma: consensus of the international conference on malignant lymphomas imaging working group. J Clin Oncol 2014 Aug 11. [Epub ahead of print]
   Web of Science ®Google Scholar
• Schimtz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autolo- gous haemopoietic stem-cell transplantation for relapsed chemosensi-tive Hodgkin's disease: a randomized trial. Lancet 2002;359:2065–2071.
   PubMed Web of Science ®Google Scholar
• Darrington DL, Vose JM, Anderson JR, et al. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. J Clin Oncol 1994;12:2527–2534.
   PubMed Web of Science ®Google Scholar
• Sureda A, Arranz R, Iriondo A, et al. Autologous stem-cell transplantation for Hodgkin's disease: Results and prognostic factors in 494 patients from the Grupo Español de Linfomas/Transplante Autológo de Médula Osea Spanish Cooperative Group. J Clin Oncol 2001;19:1395–1404.
   PubMed Web of Science ®Google Scholar
• Yahalom J, Gulati SC, Toia M, et al. Accelerated hyperfractionated total-lymphoid irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for refractory and relapsing patients with Hodgkin's disease. J Clin Oncol 1993;11:1062–1070.
   PubMed Web of Science ®Google Scholar
• Perz JB, Giles C, Szydlo R, et al. LACE-conditioned autologous stem cell transplantation for relapsed or refractory Hodgkin's lymphoma: treatment outcome and risk factor analysis in 67 patients from a single center. Bone Marrow Transplant 2007;39:41–47.
   PubMed Web of Science ®Google Scholar
• Benekli M, Smiley SL, Younis T, et al. Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma. Bone Marrow Transplant 2008;41:613–619.
   PubMed Web of Science ®Google Scholar
• Wadehra N, Farag S, Bolwell B, et al. Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation. Biol Blood Marrow Transplant 2006;12:1343–1349.
   PubMed Web of Science ®Google Scholar
• Kebriaei P, Madden T, Kazerooni R, et al. Intravenous busulfan plus melphalan is a highly effective, well tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignancies. Biol Blood Marrow Transplant 2011;17: 412–20.
   PubMed Web of Science ®Google Scholar
• Nieto Y, Thall P, Valdez B, et al. High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem cell transplantation in patients with refractory lymphoid malignancies. Biol Blood Marrow Transplant 2012;18:1677–1686.
   PubMed Web of Science ®Google Scholar
• Nieto Y, Popat U, Anderlini P, et al. Autologous stem cell transplantation for refractory or poor risk relapsed Hodgkin's lymphoma: effect of specific high dose chemotherapy regimen on outcome. Biol Blood Marrow Transplant 2013;19:410–417.
   PubMed Web of Science ®Google Scholar
• Visani G, Malerba L, Stefani PM, et al. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistent/relapsed lymphoma patients. Blood 2011;118:3419–3425.
   PubMed Web of Science ®Google Scholar
• Musso M, Scalone R, Marcacci G, et al. Fotemustine plus etoposide, cytarabine and melphalan (FEAM) as a new conditioning regimen for lymphoma patients undergoing auto-SCT: a multicenter feasibility study. Bone Marrow Transplant 2010;45:1147–1153.
   PubMed Web of Science ®Google Scholar
• Batlevi CL, Younes A. Novel therapy for Hodgkin lymphoma. Hematology 2013;2013:394–399.
   PubMed Web of Science ®Google Scholar
• Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 2012;30:2183–2189.
   PubMed Web of Science ®Google Scholar
• Kahraman D, Theurich S, Rothe A, et al. 18-Fluorodeoxyglucose positron emission tomography/computed tomography for assessment of response to brentuximab vedotin treatment in relapsed and refractory Hodgkin lymphoma. Leuk Lymphoma 2014;55:811–816.
   PubMed Web of Science ®Google Scholar
• Moskowitz AJ, Schöder H, Gerecitano J, et al. PET adapted sequential salvage therapy with brentuximab vedotin and augmented ICE for transplant eligible patients with relapsed and refractory Hodgkin lymphoma. Haematologica 2013;98(Suppl. 2): T128.
   Google Scholar
• Moskowitz A, Schoder H, Gerecitano JF, et al. FDGPET adapted sequential therapy with brentuximabvedotinand augmented ICE followed by autologous stem cell transplant for relapsed and refractory Hodgkin lymphoma. Blood 2013;122(Suppl. 1): Abstract 2099.
   PubMed Web of Science ®Google Scholar
• Garciaz S, Coso D, Peyrade F, et al. Brentuximab vedotin followed by allogeneic transplantation as salvage regimen in patients with relapsed and/or refractory Hodgkin's lymphoma. Hematol Oncol 2013 Dec 3. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• LaCasce A, Sawas A, Bociek RG, et al. A phase single arm, open-label study to evaluate the safety and efficacy of brentuximab vedotin in combination with bendamustine for patients with Hodgkin lymphoma in the first salvage setting: interim results. Biol Blood Marrow Transplant 2014;20(Suppl.):S161.
   Web of Science ®Google Scholar
• Perrot A, Monjanel H, Bouabdallah R, et al. Brentuximab vedotin as single agent in refractory or relapsed CD30-positive Hodgkin lymphoma: the French Name Patient program experience in 241 patients. Haematologica 2014;99(Suppl. 1): Abstract 3754.
   Google Scholar
• Onishi M, Holmberg L, Shustov AR, et al. Brentuximab vedotin administered to platinum-refractory transplant naïve Hodgkin lymphoma patients can increase the proportion achieving FDG-PET negative status. Blood 2013;122:S1293.
   Web of Science ®Google Scholar